The report says Medplus posted 9% YoY EBITDA growth on strong sales despite margin pressure, and retains its store addition guidance for FY27 and FY28.
Read this note →Medplus Health Services Limited
NSE MEDPLUS BSE 543427 INE804L01022
0 filings · 0 analysed
596.00
-2.77%
over today
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 29 Oct 2026, 06:40 | long | 598.05 | 880.00 | 604.60 | 2% | open by 2027-10-29 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 647.30 | 960.00 | 604.60 | -14% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report expects 20% YoY revenue growth but a decline in private label sales to impact margins, listing it as a muted performer.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief